Comparative evaluation of genotyping and low-pass sequencing for pharmacogenetic variant and phenotype inference
Hodel, F.; Thorball, C. W.; Haefliger, D.; Cerutti, L.; Cattaneo, P.; Howald, C.; Männik, K.; de La Harpe, R.; Samer, C. F.; Xenarios, I.; Fellay, J.; Girardin, F. R.
Show abstract
Background. Pharmacogenetic (PGx) testing can guide drug prescribing but remains limited by the genomic assay used. Genotyping arrays are widely implemented yet limited to predefined variants, whereas low-pass whole-genome sequencing (LP-WGS) is not constrained by fixed probe design and may provide broader PGx variant availability after imputation. Methods. We compared Illumina Global Screening Array (GSA) v3 with ~1x LP-WGS for PGx profiling in 500 hospital biobank participants with electronic health record evidence of exposure to pharmacogenetically actionable drugs and reported adverse drug reactions. Concordance was evaluated genome-wide, at 20 actionable pharmacogenes for PharmCAT-derived star alleles and metabolizer phenotypes, and for HLA alleles. Results. Genome-wide concordance between imputed array and LP-WGS data was high (median 99.63%; interquartile range, 99.59%-99.64%). For pharmacogenetically relevant variants, LP-WGS captured a larger fraction, particularly rare alleles absent from the array data, whilst maintaining high concordance at shared sites. Predicted phenotype concordance exceeded 98% for most genes, although gene-specific differences in phenotype classification were observed. LP-WGS reduced missing phenotype assignments for selected loci, particularly CYP2C19 and NAT2, by improving resolution of star-allele structure. However, in structurally complex or incompletely characterized genes such as CYP2C9 and CYP2D6, broader variant recovery increased indeterminate classifications rather than consistently improving clinical interpretability. For HLA loci, concordance varied by imputation strategy, with SNP2HLA performing marginally better utilizing the GSA array compared to the LP-WGS approach. Conclusions. Overall, LP-WGS provides broader variant coverage and improved resolution for selected pharmacogenes but did not resolve all clinically important loci. These findings support further evaluation of LP-WGS as a scalable PGx screening approach, especially where long-term genomic data reuse is a priority.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels 91%
- From Text to Translation: Using Language Models to Prioritize Variants for Clinical Review 90%
- Improving Automated Deep Phenotyping Through Large Language Models Using Retrieval Augmented Generation 89%
Similar papers in this journal
- Specification of frequency criteria for secondary findings genes to improve variant classification concordance 91%
- Genetic-Ancestry Analysis on >93,000 Individuals Undergoing Expanded Carrier Screening Reveals Limitations of Ethnicity-Based Medical Guidelines 91%
- Reducing Sanger Confirmation Testing through False Positive Prediction Algorithms 90%
Similar papers in this journal
- Validating data from Multiplex Assays of Variant Effect (MAVEs): A CanVIG-UK National Survey of NHS Clinical Scientists 91%
- Returning Actionable Genomic Results in a Research Biobank: Analytic Validity, Clinical Implementation and Resource Utilization 90%
- The Phenotype-Genotype Reference Map: Improving biobank data science through replication. 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.